These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11156147)

  • 1. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant.
    Koster A; Loebe M; Mertzlufft F; Kuppe H; Hetzer R
    Ann Thorac Surg; 2000 Dec; 70(6):2160-1. PubMed ID: 11156147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.
    Koster A; Kukucka M; Bach F; Meyer O; Fischer T; Mertzlufft F; Loebe M; Hetzer R; Kuppe H
    Anesthesiology; 2001 Feb; 94(2):245-51. PubMed ID: 11176088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade.
    Durand M; Lecompte T; Hacquard M; Carteaux JP
    Eur J Cardiothorac Surg; 2008 Sep; 34(3):687-9. PubMed ID: 18579401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of heparin and platelet GPIIbIIIa inhibitor tirofiban for cardiac surgery in patients for suspicion of heparin-induced thrombocytopenia].
    Commin PL; Rozec B; Trossaërt M; Le Teurnier Y; Fournet X; Blanloeil Y
    Ann Fr Anesth Reanim; 2006; 25(11-12):1153-7. PubMed ID: 17174215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II.
    Koster A; Meyer O; Fischer T; Kukucka M; Krabatsch T; Bauer M; Kuppe H; Hetzer R
    J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1254-5. PubMed ID: 11726910
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Pinto DS; Sperling RT; Tu TM; Cohen DJ; Carrozza JP
    Catheter Cardiovasc Interv; 2003 Jan; 58(1):65-8. PubMed ID: 12508198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of heparin upon reoperation in a pediatric patient with heparin-induced thrombocytopenia after disappearance of antibodies.
    Schreiber C; Dietrich W; Braun S; Kostolny M; Eicken A; Lange R
    Clin Res Cardiol; 2006 Jul; 95(7):379-82. PubMed ID: 16779503
    [No Abstract]   [Full Text] [Related]  

  • 8. Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment.
    Mulot A; Moulin F; Fohlen-Walter A; Angioi M; Sghaier M; Carteaux JP; Lecompte T; de Maistre E
    Am J Hematol; 2004 Sep; 77(1):67-71. PubMed ID: 15307109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass.
    von Segesser LK; Mueller X; Marty B; Horisberger J; Corno A
    Perfusion; 2001 Sep; 16(5):411-6. PubMed ID: 11565896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis.
    Lipinski MJ; Lee RC; Gaglia MA; Torguson R; Garcia-Garcia HM; Pichard AD; Satler LF; Waksman R
    Cardiovasc Revasc Med; 2016 Dec; 17(8):535-545. PubMed ID: 27842901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.
    Kim JH; Jeong MH; Rhew JY; Lim JH; Yun KH; Kim KH; Kang DK; Hong SN; Lim SY; Lee SH; Lee YS; Hong YJ; Park HW; Kim W; Ahn YK; Moon Y; Cho JG; Park JC; Kang JC
    Circ J; 2005 Feb; 69(2):159-64. PubMed ID: 15671606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two consecutive open heart operations in a small child with heparin-induced thrombocytopenia type II using anticoagulation with heparin and tirofiban.
    Neuray M; Balling G; Schreiber C; Martin K
    Ann Thorac Surg; 2012 Aug; 94(2):653-5. PubMed ID: 22579887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
    Allie DE; Hebert CJ; Lirtzman MD; Wyatt CH; Keller VA; Khan MH; Khan MA; Fail PS; Vivekananthan K; Allie SE; Mitran EV; Chaisson G; Stagg SJ; Allie AA; McElderry MW; Barker EA; Walker CM
    J Invasive Cardiol; 2005 Aug; 17(8):427-32. PubMed ID: 16079449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.
    Bizzarri F; Scolletta S; Tucci E; Lucidi M; Davoli G; Toscano T; Neri E; Muzzi L; Frati G
    J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1181-5. PubMed ID: 11726894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
    Dorsch MP; Montague D; Rodgers JE; Patterson C
    Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases.
    Abdeladim S; Elharras M; Elouarradi A; Bensahi I; Oualim S; Merzouk F; Sabry M
    Pan Afr Med J; 2021; 38():9. PubMed ID: 33520078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia.
    Caputo RP; Giambartolomei A; Simons A; Reger M; Wagner S; Esente P
    J Invasive Cardiol; 2001 Sep; 13(9):657-60. PubMed ID: 11533507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.